Placebo to vismodegib

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Metastatic Colorectal CancerOvarian Cancer

Phase 2

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

CompletedNCT00636610

Genentech, Inc.Metastatic Colorectal Cancer

Start: 2008-05-31End: 2010-12-31Updated: 2017-06-08

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

CompletedNCT00739661

Genentech, Inc.Ovarian Cancer

Start: 2008-12-31End: 2010-11-30Updated: 2017-06-08